WST vs BAX — Key Metrics

Metric WST (WEST PHARMACEUTICAL SERVICES INC) BAX (BAXTER INTERNATIONAL INC)
Price404.0226.16
Market Cap28.14 Billion13.53 Billion
P/E (TTM)45.04-18.42
P/B (Quarterly)9.7791.87
P/S (TTM)8.291.17
Net Profit Margin (TTM)18.8-6.2
Gross Margin (TTM)37.630.1
ROE (TTM)21.1-11.6
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

WEST PHARMACEUTICAL SERVICES INC
vs
 
BAXTER INTERNATIONAL INC
 
WEST PHARMACEUTICAL SERVICES INC
vs
 
BAXTER INTERNATIONAL INC
Performance Comparison
AI Model Recommendation
WST · WEST PHARMACEUTICAL SERVICES INC

Greatly Underperform

-95
UnderperformOutperform
BAX · BAXTER INTERNATIONAL INC

Greatly Outperform

88
UnderperformOutperform
Recommendation Summary

Stock WST is projected to greatly underperform the market, stock BAX is projected to greatly outperform the market. Upfront Recommendation: BAX.

Financial Metrics
Prices delayed ~15 min
WST Metrics BAX
$404.02 Price $26.16
— Market Capitalization —
8.29 Price to Sales 1.17
48.5 Price to FCF Ratio 11.93
22.04 Price to Gross Profit 3.87
372.28 Price to R&D 26.08
15.49 Price to Current Assets 1.98

WST vs BAX at a glance

West Pharmaceutical Services INC (WST) and Baxter International INC (BAX) are both Medical Instruments & Supplies companies in the Healthcare sector. WST is the larger, at $28.1 billion in market value against $13.5 billion for BAX, about 2.1 times the size.

On trailing-twelve-month figures, WST trades at 8.3 times trailing sales and BAX at 1.2; net profit margins are 18.8% and -6.2%.

The Upfront Investment model currently rates WST Greatly Underperform and BAX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.